As the anticipation for ASH 2023 builds, Professor Graham Jackson, consultant haematologist and Myeloma UK’s Chief Clinical and Scientific Advisor, sheds light on the top abstracts to watch, offering a curated glimpse into the forefront of myeloma research.
New research has uncovered a concerning gap in the time taken to diagnose myeloma between ethnic groups, with black people experiencing longer waits for a diagnosis than white people. The study showed that black patients diagnosed with myeloma had a median wait time of over one month longer than white people.
This important virtual national conference provides an essential update for current and aspiring non medical prescribers on prescribing at the end of life. It is widely recognized that pain and symptom control at the end of life is not always optimal, the development of non medical prescribing has a key role in improving pain and…
Results from two phase III clinical trials (MAIA and CASSOPIEA) evaluating daratumumab (Darzalex®) combinations for the treatment of newly diagnosed myeloma patients have been recently published. The data provide evidence to support the use of daratumumab for the treatment of newly diagnosed myeloma patients whether they are eligible for high dose therapy and stem cell…
The Myeloma Diagnosis Pathway is an easy to follow, quick reference tool to help GPs and other healthcare professionals recognise the signs and symptoms of myeloma. It provides information on which tests and investigations should be conducted before referral to a haematologist. It has been designed by Myeloma UK and reviewed by a working group…
A study examining the number of visits people made to their GP before being diagnosed with cancer through accident and emergency (A&E) has shown that myeloma patients presenting via this route have the highest number of prior GP visits than any other cancer. Published recently in the British Journal Of General Practice, researchers from the Universities of…
Myeloma UK together with the British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) have jointly published new guidelines for the screening and management of the late and long-term consequences of myeloma and its treatments. Published recently in the British Journal of Haematology, the guidelines highlight the key late effects…
A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
